How molecularly similar are primary and metastatic tissues in renal cell carcinoma?

Affiliations

¹ Department of Medical Oncology, Gazi University, Ankara 06560, Turkey; Department of Medical Oncology, Gazi University, Emniyet, Mevlana Blv. No:29, 06560 Yenimahalle, Ankara, Turkey. Electronic address: burcuulas@gazi.edu.tr.
² Department of Medical Oncology, Gazi University, Ankara 06560, Turkey; Department of Medical Oncology, Gazi University, Emniyet, Mevlana Blv. No:29, 06560 Yenimahalle, Ankara, Turkey.

Comment

Burcu Ulaş Kahya et al. Lancet Oncol. 2022 Jul.

. 2022 Jul;23(7):e316.

doi: 10.1016/S1470-2045(22)00330-8.

¹ Department of Medical Oncology, Gazi University, Ankara 06560, Turkey; Department of Medical Oncology, Gazi University, Emniyet, Mevlana Blv. No:29, 06560 Yenimahalle, Ankara, Turkey. Electronic address: burcuulas@gazi.edu.tr.
² Department of Medical Oncology, Gazi University, Ankara 06560, Turkey; Department of Medical Oncology, Gazi University, Emniyet, Mevlana Blv. No:29, 06560 Yenimahalle, Ankara, Turkey.

No abstract available

Conflict of interest statement

We declare no competing interests.

How molecularly similar are primary and metastatic tissues in renal cell carcinoma? - Authors' reply.
Vano YA, Elaidi R, Phan L, Meylan M, Fridman WH, Sautès-Fridman C, Oudard S; BIONIKK co-investigators. Vano YA, et al. Lancet Oncol. 2022 Jul;23(7):e317. doi: 10.1016/S1470-2045(22)00344-8. Lancet Oncol. 2022. PMID: 35772459 No abstract available.

Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.
Vano YA, Elaidi R, Bennamoun M, Chevreau C, Borchiellini D, Pannier D, Maillet D, Gross-Goupil M, Tournigand C, Laguerre B, Barthélémy P, Coquan E, Gravis G, Houede N, Cancel M, Huillard O, Beuzeboc P, Fournier L, Méjean A, Cathelineau X, Doumerc N, Paparel P, Bernhard JC, de la Taille A, Bensalah K, Tricard T, Waeckel T, Pignot G, Braychenko E, Caruso S, Sun CM, Verkarre V, Lacroix G, Moreira M, Meylan M, Bougouïn A, Phan L, Thibault-Carpentier C, Zucman-Rossi J, Fridman WH, Sautès-Fridman C, Oudard S. Vano YA, et al. Lancet Oncol. 2022 May;23(5):612-624. doi: 10.1016/S1470-2045(22)00128-0. Epub 2022 Apr 4. Lancet Oncol. 2022. PMID: 35390339 Clinical Trial.